<div id="readability-page-1"><p>Lazard Asset Management LLC lifted its position in  Labcorp Holdings Inc. (NYSE:LH - Free Report) by 224.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor  owned 989,433 shares of the medical research company's stock after buying an additional 684,153 shares during the period. Lazard Asset Management LLC owned approximately 1.19% of Labcorp worth $259,734,000 at the end of the most recent reporting period.</p><ul><li>Joby and Archer Forge a New Strategic Chapter in the UAE</li></ul><p>Other large investors have also bought and sold shares of the company. Brighton Jones LLC acquired a new stake in  Labcorp in the 4th quarter valued at about $991,000.  Townsquare Capital LLC boosted its holdings in  Labcorp by 8.8% during the first quarter. Townsquare Capital LLC now owns 4,785 shares of the medical research company's stock worth $1,114,000 after buying an additional 389 shares in the last quarter.  Nuveen LLC acquired a new position in  Labcorp in the first quarter worth approximately $48,193,000.  Public Sector Pension Investment Board grew its position in  Labcorp by 8.7% in the first quarter. Public Sector Pension Investment Board now owns 11,418 shares of the medical research company's stock worth $2,657,000 after buying an additional 913 shares during the last quarter.  Finally, Resona Asset Management Co. Ltd. lifted its position in shares of  Labcorp by 5.5% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 26,981 shares of the medical research company's stock valued at $6,268,000 after acquiring an additional 1,413 shares during the last quarter. Institutional investors own  95.94% of the company's stock. </p><h2>Labcorp Stock Down 0.2%</h2><p>LH opened at $264.15 on Friday. The company has a market capitalization of $21.90 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.99. The business has a 50-day moving average of $267.56 and a 200-day moving average of $266.08. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.35. </p><ul><li>Palantir’s Defense Partnerships Fuel Its Growth Story</li></ul><p>Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $4.18 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.05. The firm had revenue of $3.56 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. The company's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.50 earnings per share. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS.  Equities research analysts forecast that  Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year. </p><h2>Labcorp Announces Dividend</h2><p>The business also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Wednesday, November 26th were given a $0.72 dividend. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp's payout ratio is currently 28.29%. </p><h2>Insider Activity</h2><ul><li>Next-Gen Defense: 3 Stocks Riding the New Global Arms Race</li></ul><p>In other news, CEO Adam H. Schechter sold 5,745 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $262.75, for a total transaction of $1,509,498.75. Following the transaction, the chief executive officer owned 87,574 shares of the company's stock, valued at approximately $23,010,068.50. This represents a 6.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richelle P. Parham sold 7,009 shares of the firm's stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $254.28, for a total value of $1,782,248.52. Following the completion of the transaction, the director directly owned 2,469 shares in the company, valued at $627,817.32. The trade was a 73.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own  0.84% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>LH has been the subject of several analyst reports. Wall Street Zen downgraded Labcorp from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Mizuho upped their price objective on shares of Labcorp from $285.00 to $320.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, October 17th. JPMorgan Chase &amp; Co. boosted their price target on shares of Labcorp from $291.00 to $317.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, November 7th. Barclays lifted their price target on Labcorp from $275.00 to $290.00 and gave the company an &#34;equal weight&#34; rating in a report on Thursday, October 2nd. Finally, UBS Group reduced their price objective on Labcorp from $325.00 to $320.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, October 29th. Eleven investment analysts have rated the stock with a Buy rating and four have issued  a Hold rating to the company's stock. Based on data from MarketBeat, Labcorp  has an average rating of &#34;Moderate Buy&#34; and an average price target of $299.08.</p><p><b>View Our Latest Research Report on LH</b></p><h2>Labcorp Company Profile</h2> (Free Report)<p>Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC. </p><h2>See Also</h2><ul><li>Five stocks we like better than Labcorp</li><li>Consumer Discretionary Stocks Explained</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>MarketBeat Week in Review – 12/8 - 12/12</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxI"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Labcorp Right Now?</h2><p>Before you consider Labcorp, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.</p><p>While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Lazard Asset Management LLC increased its stake in Labcorp Holdings Inc. by 224.1% in Q2, owning 989,433 shares worth $259.7 million. Other investors also adjusted their positions in Labcorp. The company reported Q3 earnings of $4.18 per share, beating estimates, with revenue up 8.6% year-over-year. Labcorp announced a quarterly dividend of $0.72 per share. Insider sales included CEO Adam Schechter and Director Richelle Parham. Analysts have mixed ratings on Labcorp, with Mizuho raising its price target.</p>

Labcorp Holdings Inc. $LH Shares Bought by Lazard Asset Management LLC